NCT04419909View on ClinicalTrials.gov

Retreatment With CTL019/CTL119

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 31, 2026

Primary Completion Date

July 31, 2028

Study Completion Date

July 31, 2028

Conditions
Lymphoma, B-Cell
Interventions
DRUG

CD19 redirected autologous T cells (CTL019 or CTL119 cells)

Retreatment with CD19-directed Chimeric Antigen Receptor-modified T Cells (CART19 cells) or huCD19-directed Chimeric Antigen Receptor-modified T Cells (huCART19 cells) in subjects with late relapse of B-cell lymphomas.

Trial Locations (1)

19104

University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

University of Pennsylvania

OTHER